Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...

Santa Claus will soon be on his way delivering presents to kids around the world. But could the jolly gift-giver bring ...

Novo Nordisk ’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out ...

The Food and Drug Administration today approved Eli Lilly’s weight-loss treatment, Zepbound, for obstructive sleep apnea, ...

A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.

Novo Nordisk has told the world it expects patients to lose “at least 25%” of their body weight on its experimental drug ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

(Reuters) -The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for ...

Skipping certain foods can help patients manage nausea and other side effects of the popular drugs, doctors say.